Update on the management of hyperuricemia and gout.
Gout is the most common inflammatory arthritis in the United States, with more than three million sufferers. Management of gout has changed relatively little in the past 50 years, despite the fact that many gout patients have contraindications to one or more currently available gout therapies. However, recent insights into gout pathophysiology suggest that time is ripe for a change. This article reviews recent updates in the management of gout, including new insights into dietary management that may permit better control of hyuperuricemia. Also reviewed are the biological and clinical data behind newly-developed drugs for gout that are likely to receive serious consideration for FDA approval, and clinical use, in the foreseeable future.
Pillinger
Michael H
MH
New York Universuty School of Medicine, New York, NY, USA. michael.pillinger@med.nyu.edu
Keenan
Robert T
RT
D000324:Adrenocorticotropic Hormone / Q000627:therapeutic use; D000428:Alcohol Drinking / Q000009:adverse effects; D003069:Coffee; D016207:Cytokines / Q000037:antagonists & inhibitors; D003611:Dairy Products; D004032:Diet / Q000009:adverse effects; D004040:Dietary Carbohydrates / Q000009:adverse effects; D015507:Drugs, Investigational / Q000627:therapeutic use; D005632:Fructose / Q000009:adverse effects; D006073:Gout / Q000209:etiology / Q000276:immunology / Q000628:therapy*; D006074:Gout Suppressants / Q000627:therapeutic use*; D006801:Humans; D033461:Hyperuricemia / Q000209:etiology / Q000276:immunology / Q000628:therapy*; D044101:Receptors, Melanocortin / Q000819:agonists; D040242:Risk Reduction Behavior; D016896:Treatment Outcome
D003069:Coffee; D016207:Cytokines; D004040:Dietary Carbohydrates; D015507:Drugs, Investigational; D006074:Gout Suppressants; D044101:Receptors, Melanocortin; D005632:Fructose; D000324:Adrenocorticotropic Hormone